Nanomix Corporation announced the appointment of Dr. Thomas Schlumpberger as member of the Board of Directors, effective immediately. Dr. Schlumpberger is a recognized expert in POC diagnostics and a seasoned senior executive with more than 20 years in the life sciences industry.  His broad base of experience is directly applicable to the next phase of growth at Nanomix as the Company's POC platform gains customer adoption.  At Epocal, a POC company, he was responsible for international business and business development. He successfully launched a point-of-care product in India, Japan and Europe and, notably, he led the sale of Epocal to Alere.

At Singulex, he concluded an investment from Grifols and successfully launched an ultra-high sensitivity assay in Europe. Most recently, as CEO of Pictor Limited, he successfully revamped the product portfolio and launched a COVID-19 antibody product successfully into several CLIA-certified laboratories.  Dr. Schlumpberger has held senior executive roles with several other diagnostic companies, including Anixa, InVitae, Inivata, and Affymetrix.  He received his Ph.D. in molecular and cell biology with distinction from the University of California, Berkeley.